MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
MetaVia (Nasdaq: MTVA) will highlight its pipeline of novel obesity and metabolic therapies in a fireside chat at the Life Sciences Virtual Investor Forum on June 24, 2026 at 10:30 am ET, a live, interactive event co-hosted by Zacks Small Cap Research.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MetaVia (Nasdaq: MTVA) will highlight its pipeline of novel obesity and metabolic therapies in a fireside chat at the Life Sciences Virtual Investor Forum on June 24, 2026 at 10:30 am ET, a live, interactive event co-hosted by Zacks Small Cap Research.
Details
News Market Reaction – MTVA
On Jun 17, the day this news came out, MTVA closed 3.64% above the previous close.
Data tracked by StockTitan Argus for the Jun 17 session.
Key Figures
- Conference date
- June 24, 2026
- Life Sciences Virtual Investor Forum presentation
- Presentation time
- 10:30 am ET
- Scheduled fireside chat at virtual forum
Historical Context
-
Shared new DA-1726 obesity and metabolic data from ADA 2026 sessions.
-
Announced upcoming Emerging Growth Conference presentation on obesity pipeline.
-
Reported higher-dose Phase 1 DA-1726 results with significant weight loss signals.
-
Highlighted publication supporting vanoglipel’s anti-fibrotic and metabolic potential in MASH.
-
Announced acceptance of three late-breaking abstracts for ADA 2026 presentations.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This will be a live, interactive online forum where investors are invited to ask the company questions in real-time. If attendees are not able to join the live event on the day of the conference, an archived webcast will also be made available after the conclusion of the forum.
It is recommended that investors pre-register using this link and run the online system check to expedite participation and receive event updates.
MetaVia will be available for one-on-one meetings; investors may register using this link. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). In preclinical studies, vanoglipel demonstrated a positive metabolic effect on glucose and lipid control, and also proved differentiated hepatic benefits reducing hepatic steatosis, hepatic inflammation, and liver fibrosis regardless independent of metabolic improvement. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content:https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-life-sciences-virtual-investor-forum-302803076.html
SOURCE MetaVia Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.